The role of osteoprotegrin/nuclear factor kB ligand in coronary collateral development

European Journal of Inflammation

Volumn 9, Issue 1, 2011, Pages 57-64

  Maghbooli, Z ^a   Hossein Nezhad, Arash ^a   Shirzad, M ^b   Behzadi, H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CAD; Collateralization; Osteoprotegrin; RANKL

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGRIN; PROTEGRIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE SEVERITY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA EXTRACTION;

EID: 81755169077     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900109     Document Type: Article

References (28)

1. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and actors influencing collateral channel development: functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol 2001; 38:1872-78. (Pubitemid 33116557)
2. Annex BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005; 65:649-55. (Pubitemid 40138985)
3. Collin-Osdoby P. Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin. Circ Res 2004; 95:1046-57. (Pubitemid 39557891)
4. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7. (Pubitemid 28319153)
5. McGonigle JS, Giachelli CM. Marta Scatena. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12:35-46.
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12. (Pubitemid 30026926)
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76. (Pubitemid 28180851)
8. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-02.
9. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280:334-39. (Pubitemid 32917516)
10. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86:631-37. (Pubitemid 32207471)
11. Furuya D, Kaneko R, Yagihashi A, Endoh T, Yajima T, Kobayashi D, Yano K, Tsuda E, Watanabe N. Immuno-PCR assay for homodimeric osteoprotegerin. Clin Chem 2001; 47:1475-77. (Pubitemid 32678832)
12. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegrin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-68. (Pubitemid 28213402)
13. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alpha(v) integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 2008; 76:139-44.
14. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004; 89:3764-68. (Pubitemid 39071469)
15. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-94. (Pubitemid 34988634)
16. Kiechl S, Schert G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-80. (Pubitemid 38625393)
17. Dovio A, Data V, Angeli A. Circulating osteoprotegrin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 2005; 28:14-22.
18. Campenhout AV, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204:321-29.
19. Kinnaird T, Stabile E, Zbinden S, Burnett M, Epstein SE. Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. Cardiovascular Research 2008; 78:257-64.
20. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5:587-92. (Pubitemid 15141963)
21. Sandberg WJ, Yndestad A, Øie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26:857-63. (Pubitemid 43732163)
22. Chittenden TW, Sherman JA, Xiong F, et al. Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation. 2006; 114:1811-20. (Pubitemid 44673356)
23. Kiechl S, Werner P, Knoflach M, et al. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4:801-11. (Pubitemid 46017520)
24. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-80. (Pubitemid 38625393)
25. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44:1970-76. (Pubitemid 39473280)
26. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006; 26:2117-24. (Pubitemid 44253797)
27. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117:411-20.
28. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG):a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 2006; 118:1901-8.